Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
New Ionic Liquid Forms of Antituberculosis Drug Combinations for Optimized Stability and Dissolution.
AAPS PharmSciTech
January 2025
Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut, Egypt.
Isoniazid (INH) and rifampicin (RIF) are the two main drugs used for the management of tuberculosis. They are often used as a fixed drug combination, but their delivery is challenged by suboptimal solubility and physical instability. This study explores the potential of active pharmaceutical ingredient-ionic liquids (API-ILs) to improve the physicochemical and pharmaceutical properties of INH and RIF.
View Article and Find Full Text PDFAluminum Cluster Molecular Ring-Based Heterometallic Framework Materials for Iodine Capture.
Inorg Chem
January 2025
College of Chemistry and Chemical Engineering, Qingdao University, Shandong 266071, P. R. China.
With the development of the nuclear industry, the risk of elements that are difficult to degrade in nuclear fission has been gradually increasing. Therefore, the efficient capture of iodine (I) has attracted considerable attention in recent years. The aluminum cluster-based metal framework materials show great advantage in iodine adsorption due to the designable pore sizes, excellent physicochemical stability, and cheap raw materials.
View Article and Find Full Text PDFHair isoniazid levels predict TB sputum culture conversion.
Int J Tuberc Lung Dis
January 2025
Department of Pharmacology and Therapeutics, Makerere College of Health Sciences, Kampala, Uganda.
Rifampicin and isoniazid resistance not promote fluoroquinolone resistance in Mycobacterium smegmatis.
PLoS One
January 2025
National Clinical Research Center for Infectious Diseases, Shenzhen Clinical Research Center for Tuberculosis, Shenzhen Third People's Hospital, Shenzhen, Guangdong, China.
Background: The emergence of drug-resistant Tuberculosis (TB) has made treatment challenging. Although fluoroquinolones (FQs) are used as key drugs in the treatment of multidrug-resistant tuberculosis (MDR-TB), the problem of FQs resistance is becoming increasingly serious. Rifampicin (RIF) resistance is considered a risk factor for FQs resistance.
View Article and Find Full Text PDFClinical predictors of 3-month isoniazid rifapentine (3HP)-related adverse drug reactions (ADR) during tuberculosis preventive therapy (PAnDoRA-3HP study): an observational study protocol.
BMJ Open
December 2024
Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Central, Uganda.
Introduction: Tuberculosis (TB) is the leading infectious cause of death globally. Despite WHO recommendations for TB preventive therapy (TPT), challenges persist, including incompletion of treatment and adverse drug reactions (ADRs). There is limited data on the 3-month isoniazid and rifapentine (3HP) pharmacokinetics, pharmacogenomics and their relation with ADRs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!